MedTrace Logo

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.

NCT05451862 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-08-26

No results posted yet for this study

Summary

166Ho-TARE is a promising modality for the treatment of HCC, given the unique characteristics of holmium, allowing careful patient selection and personalized dosimetry treatment planning. Further clinical evidence is needed to evaluate the safety and efficacy of 166Ho-TARE in the treatment of HCC patients with limited tumor burden, well preserved liver function and performance status and ineligible for liver transplantation and/or liver resection. This study will also provide further evidence on the dose-response relationship of 166Ho-TARE in (early) HCC.

Conditions

Interventions

DEVICE

Holmium-166 treatment

Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.

DEVICE

Holmium-166 work-up

Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.

Sponsors & Collaborators

  • Terumo Europe N.V.

    lead INDUSTRY

Principal Investigators

  • Jens Ricke, Prof. Dr. med · Ludwig-Maximilian-University Munich (LMU)

  • Wolfgang Weber, Prof. Dr. med · Munich Technische Universität (TUM)

  • Thomas Kröncke, Prof. Dr. med · Universitätsklinikum Augsburg

  • Ralph Kickuth, Prof. Dr. med · Wuerzburg University Hospital

  • Karin Menhart, Dr. · Universitätsklinikum Regensburg

  • Peter Dietrich, PD. Dr. med. · Uniklinikum Erlangen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-21
Primary Completion
2025-05-27
Completion
2025-05-27

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05451862 on ClinicalTrials.gov